Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Psoriasiform Dermatitis After Initiation of Treatment with Dupilumab for Atopic Dermatitis

Fowler, Emilie, BS*†; Silverberg, Jonathan I., MD, PhD, MPH‡§; Fox, Joshua D., MD*; Yosipovitch, Gil, MD*†

doi: 10.1097/DER.0000000000000481

From the *Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and

Miami Itch Center, University of Miami Miller School of Medicine, FL; and

Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine at Northwestern University; and

§Northwestern Medicine Multidisciplinary Eczema Center, Chicago, IL.

Address reprint requests to Gil Yosipovitch, MD, 1600 NW 10th Ave, RMSB 2067B, Miami, FL 33136. E-mail:

G.Y. has been a consultant or advisory board member of Menlo, TREVI, Sienna, Galderma, Sanofi, Regeneron, Novartis, Eli Lilly, and Pfizer and received research grants from Sun Pharma, Pfizer, and Leo Foundation. J.I.S. served as a consultant and/or advisory board member for Abbvie, Asana, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi, Realm, and Roivant for granting honoraria and as speaker for Regeneron-Sanofi and received research grants from GlaxoSmithKline and Regeneron-Sanofi. J.I.S. is supported by the DermatologyFoundation.

© 2019 American Contact Dermatitis Society
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website